TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2026-11 · 1872 (8) · 168368
DOI: 10.1016/j.bbadis.2026.168368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2026-11. Verfasst von Qi Ouyang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, …. Hauptthemen laut MEDLINE: Glucosides, Colitis, Ulcerative, Phenols, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The absence of known inhibitors for TNFAIP1, a TNF-α-induced protein, has limited its exploration as a therapeutic target for ulcerative colitis (UC). This study aimed to validate TNFAIP1's pathogenic role in UC and to identify the first direct TNFAIP1-targeting compound from natural compounds. METHODS: We integrated bioinformatics analysis, DSS-induced colitis models in Tnfaip1-knockout mice, and virtual screening to identify Salidroside as a potential TNFAIP1-targeting compound. Cellular thermal shift and ubiquitination assays confirmed its direct interaction with TNFAIP1 and its effect on protein stability. Oral administration of Salidroside ameliorated colitis in wild-type mice, phenocopying the protective effect of Tnfaip1 deficiency. RESULTS: TNFAIP1 was significantly upregulated in UC patients and colitic mice. Tnfaip1-knockout conferred profound resistance to colitis, mechanistically linked to the suppression of the IKK/IκB/NF-κB pathway, modulation of CREB signaling, and restoration of a beneficial gut microbiota. Based on this target validation, virtual screening identified Salidroside as a top candidate. Crucially, Salidroside administration in wild-type mice phenocopied the protective effects of genetic knockout, alleviating disease severity and downregulating the TNFAIP1-driven inflammatory network. CETSA confirmed a direct physical interaction between Salidroside and TNFAIP1. CONCLUSION: This study validates TNFAIP1 as a key pathogenic driver of UC and identifies Salidroside as a first-in-class direct TNFAIP1-targeting compound with therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China.
- Engineering Research Center for Antibodies from Experimental Animals of Hunan Province, College of Life Sciences, Hunan Normal University, Changsha, China.
- Engineering Research Center for Antibodies from Experimental Animals of Hunan Province, College of Life Sciences, Hunan Normal University, Changsha, China. Electronic address: xshlin@hunnu.edu.cn.
- The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China. Electronic address: huxiang@hunnu.edu.cn.
Zitieren
APA
Ouyang, Q., Tian, S., Jiang, H., Li, M., Zeng, Y., Zhao, L., Zhou, F., Xiang, S., & Hu, X. (2026). TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872(8), 168368. https://doi.org/10.1016/j.bbadis.2026.168368
Vancouver
Ouyang Q, Tian S, Jiang H, Li M, Zeng Y, Zhao L, et al. TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(8):168368. doi:10.1016/j.bbadis.2026.168368
BibTeX
@article{Ouyang2026,
author = {Ouyang, Qi and Tian, Shengye and Jiang, Hong and Li, Moyong and Zeng, Yuteng and Zhao, Linhui and Zhou, Fang and Xiang, Shuanglin and Hu, Xiang},
title = {TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2026},
volume = {1872},
number = {8},
pages = {168368},
doi = {10.1016/j.bbadis.2026.168368}
}
EUVIMED